USD 19226.51 Million in 2024; projected USD 35140.74 Million by 2033; CAGR 6.92%.

Snapshot img

Travel Vaccines Market Size 2025-2029

The travel vaccines market size is forecast to increase by USD 7.05 billion, at a CAGR of 10.7% between 2024 and 2029.

Major Market Trends & Insights

North America dominated the market and accounted for a 46% growth during the forecast period.
By the Disease Type - Influenza segment was valued at USD 3.44 billion in 2023
By the End-user - Adult vaccines segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: USD 112.15 billion
Market Future Opportunities: USD 7.05 billion 
CAGR : 10.7%
North America: Largest market in 2023

Market Summary

The market is a significant sector within the healthcare industry, demonstrating continuous growth and evolution. According to various market research, the demand for travel vaccines is on the rise, with an estimated 250 million international travelers in 2020. This number is projected to reach 380 million by 2027, representing a substantial increase. Travelers' changing demographics and increased global connectivity contribute to this market expansion. For instance, an aging population and the rise of adventure tourism are key factors driving the need for diverse travel vaccines. Moreover, the market is witnessing the emergence of new vaccine types, such as combination vaccines, which offer enhanced protection against multiple diseases.
The market's dynamism is further fueled by advancements in technology, enabling the development of more effective and convenient vaccine delivery methods. For example, the use of microneedle patches and oral vaccines is gaining popularity due to their ease of administration and improved patient compliance. Despite these positive trends, challenges persist, including the lack of comprehensive vaccine coverage in some health plans and the ongoing impact of the COVID-19 pandemic on travel vaccination services. Nonetheless, the market's potential for growth remains strong, with opportunities for collaboration between stakeholders, including pharmaceutical companies, travel agencies, and healthcare providers.

What will be the Size of the Travel Vaccines Market during the forecast period?

Explore market size, adoption trends, and growth potential for travel vaccines market Request Free Sample

Travel vaccines represent a significant segment within the healthcare industry, with current market participation exceeding 20%. This figure underscores the importance of travel vaccines in safeguarding the health of globally mobile populations. Looking ahead, market expansion is anticipated to surpass 15% annually, driven by increasing awareness of disease prevention and the continuous development of innovative vaccine formulations. The market demonstrates a dynamic equilibrium between vaccine efficacy and patient compliance. For instance, in 2020, vaccine recommendations for hepatitis A and typhoid fever reached 90% and 70%, respectively, reflecting high levels of adherence. In contrast, compliance for yellow fever and rabies vaccines stood at 60% and 40%, respectively.
This disparity underscores the importance of effective vaccine education and public health initiatives to boost compliance rates and ultimately improve disease prevention. Moreover, advancements in vaccine manufacturing, cold chain management, and adjuvant systems have led to increased vaccine availability and efficacy. For example, cellular immunity responses to certain vaccines have shown promising results, leading to enhanced protection against various diseases. These advancements not only contribute to the market's growth but also improve overall traveler health and safety.

How is this Travel Vaccines Industry segmented?

The travel vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Disease Type

  Influenza
  Diptheria
  Hepatitis
  Typhoid and others


End-user

  Adult vaccines
  Pediatric vaccines


Type

  Outbound
  Inbound


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Disease Type Insights

The influenza segment is estimated to witness significant growth during the forecast period.

The market, specifically for influenza, is experiencing substantial expansion due to several factors. The resurgence of leisure and corporate travel to pre-pandemic levels and the increasing health awareness among travelers are primary drivers. Influenza vaccines are easily accessible, as they are widely available at pharmacies, healthcare facilities, and workplaces, making administration convenient for travelers. Moreover, disease surveilla

Europe Cancer Vaccines Market is segmented by Technology, Treatment Method (Preventive Vaccine and Therapeutic Vaccine), Application and Geography.

The global travel vaccines market is booming, projected to reach $9.5 billion by 2033, driven by rising international travel and increasing vaccine awareness. Learn about market trends, key players (Pfizer, GSK, Sanofi), and regional insights in this comprehensive analysis. Recent developments include: March 2024: The UAE Ministry of Health and Prevention (MoHAP) mandated influenza vaccination for pilgrims traveling to Saudi Arabia. It was a preventive measure to protect the Hajj performers, their families, and all segments of society from infectious diseases., February 2024: The University of Kentucky’s UK Retail Pharmacies started offering travelers all the required and recommended vaccines based on their destination, including yellow fever, typhoid, and cholera., May 2023: Bavarian Nordic acquired Emergent BioSolutions’ travel vaccine portfolio for USD 274 million. The deal encompassed the acquisition of vaccines Vivotif and Vaxchora, marketed for the prevention of typhoid and cholera, respectively, and a phase III vaccine candidate for the prevention of the chikungunya virus.. Key drivers for this market are: Significant Rise in Outbound Tourism, Prevalence of Hepatitis A Across Most Travelled Destinations; Increasing Meetings, Incentives, Conferences, and Exhibitions (MICE) in Different Nations. Potential restraints include: Significant Rise in Outbound Tourism, Prevalence of Hepatitis A Across Most Travelled Destinations; Increasing Meetings, Incentives, Conferences, and Exhibitions (MICE) in Different Nations. Notable trends are: The Hepatitis A Segment is Expected to Witness Significant Growth During the Forecast Period.

The Europe Veterinary Vaccine Market is projected to grow at a CAGR of around 5.5% during the forecast period 2021-2026 says- MarkNtel Advisors.

Snapshot img

Vaccines Market Size 2025-2029

The vaccines market size is forecast to increase by USD 160.22 billion at a CAGR of 23.1% between 2024 and 2029.

The market is experiencing significant growth, driven by increased funding for research and development, leading to the launch of new vaccines. One of the most promising trends in this market is the development of nanoparticle vaccines, which offer enhanced immunogenicity and improved delivery systems. This trend is particularly evident in the development of nanoparticle vaccines, which offer enhanced efficacy and safety. However, the high cost of research, development, and manufacturing poses a significant challenge for market players. Examples include the inactivated polio vaccine (IPV) and influenza vaccine. These costs can be attributed to the complex production processes involved in vaccine creation, as well as the need for rigorous clinical trials to ensure safety and efficacy. 
However, the high cost of vaccine research, development, and manufacturing remains a significant challenge for market participants. Despite this, the market presents numerous opportunities for companies seeking to capitalize on the growing demand for vaccines, particularly in emerging economies with rising healthcare expenditures. Strategic partnerships, collaborations, and acquisitions are key strategies for companies looking to navigate the competitive landscape and stay ahead of the curve.
Overall, the market is poised for continued growth, with significant opportunities for innovation and investment in the coming years. Companies that can effectively address the challenges of cost and regulatory compliance while delivering high-quality, effective vaccines will be well-positioned to succeed.

What will be the Size of the Vaccines Market during the forecast period?

Request Free Sample

The market driven by the continuous development of immunization programs and the pursuit of vaccine equity. Immunological memory, antibody response, and cost-effectiveness analysis are key factors influencing market growth. Vaccine supply chain, efficacy testing, preservation, patent, and licensing are essential aspects of the market. Nanotechnology and universal vaccines are emerging trends, aiming to improve vaccine accessibility and quality control. Vaccine manufacturing, regulatory approval, and economic impact are crucial elements in the market, with intellectual property, vaccine shelf life, and vaccine development pipeline being significant factors.
Vaccine innovation and vaccine safety monitoring are essential for addressing disease burden and ensuring potency, stability, and sterility. Vaccine logistics and vaccine stability are critical for successful distribution and administration, while vaccine safety monitoring emphasizes the importance of ongoing surveillance and immune response assessment. 

How is this Vaccines Industry segmented?

The vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Subunit vaccines
  Live attenuated vaccines
  Inactivated vaccines
  Toxoid vaccines
  Others


End-user

  Hospitals
  Clinics


Technology

  mRNA vaccines
  Viral vector vaccines
  Protein based vaccines
  DNA vaccines
  Others


Route Of Administration

  Intramuscular
  Subcutaneous
  Oral
  Intranasal
  Others


Disease Type

  Influenza
  Human papillomavirus
  Hepatitis
  Measles
  mumps
  rubella
  Others


Age Group

  Pediatric
  Adult
  Adolescent
  Geriatric


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Type Insights

The subunit vaccines segment is estimated to witness significant growth during the forecast period.

Subunit vaccines, integral components of the healthcare system's disease prevention strategy, employ specific antigenic pieces of a pathogen, such as proteins, sugars, or capsids, to induce a robust immune response. These vaccines, including the mRNA vaccines, are designed to target specific components of the pathogen, making them highly effective in preventing infections. The development process involves identifying and isolating these antigenic components, followed by formulation and rigorous testing to ensure safety and efficacy. For instance, in the realm of disease outbreak prevention, a phase 3 trial for the subunit TB vaccine candidate M72/AS01E was initiated in March 2024 in South Africa.

This trial aims to evaluate the vaccine's efficacy in preventing the progression from latent TB to active pulmonary TB, contributing to herd immunity and ultimately, disease surveillance and vaccine distribution within the healthcare system.

The Europe Vaccine market is anticipated to add more than USD 7 Billion from 2023 to 2028 due to strong healthcare systems.

In Europe Bacterial Vaccines Market, offering valuable insights, key market trends, competitive landscape, and future outlook to support strategic decision.

The Market Report Covers Europe Veterinary Vaccine Manufacturers and is Segmented by Animal Vaccine Type (Livestock Vaccines and Companion Animal Vaccines), Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Technologies), and Geography (Germany, United Kingdom, France, Italy, Spain and Rest of Europe). The Value is Provided in (USD Million) for the Above Segments.

The value of Germany's mRNA combined vaccines and therapies market is forecast to reach around *** billion U.S. dollars by the end of 2030. In 2020, the market was estimated at approximately *** billion U.S. dollars. This would represent a compound annual growth rate of around *** percent between 2020 and 2030. More information on the global mRNA vaccines and therapies market can be found here.

In Europe Aquaculture Vaccines Market, offering valuable insights, key market trends, competitive landscape, and future outlook to support strategic decision.

Learn about the projected growth of the vaccines market in the European Union, with market volume expected to reach 32K tons and market value to hit $50B by 2035.

Europe Chicken Vaccines accounted for a share of over 30% of the global market size of USD XX million in 2023 and projected to expand at a CAGR of 6.5% from 2023 to 2030.

The global childhood vaccines market is a significant and rapidly expanding sector, projected to experience substantial growth over the forecast period (2025-2033). While precise market size figures for 2019-2024 are unavailable, we can infer substantial growth based on the presence of major pharmaceutical players like GSK, Sanofi, Pfizer, and Merck, coupled with increasing global vaccination initiatives. The market is driven by rising awareness of vaccine-preventable diseases, stringent government regulations mandating childhood vaccinations, and the continuous development of advanced vaccine technologies such as recombinant and viral vaccines. Furthermore, the increasing prevalence of vaccine-preventable diseases in developing economies fuels market expansion. However, factors such as vaccine hesitancy, adverse effects concerns, and high vaccine costs pose challenges to market growth. The market is segmented by application (hospital, clinic) and vaccine type (recombinant, viral, polysaccharide, and others). Recombinant and viral vaccines are expected to dominate owing to their effectiveness and safety profile. Geographically, North America and Europe currently hold significant market shares due to advanced healthcare infrastructure and high vaccination rates. However, Asia Pacific is projected to witness the fastest growth due to rising disposable incomes, improving healthcare infrastructure, and increasing government initiatives promoting vaccination programs. The competitive landscape is characterized by the presence of both multinational pharmaceutical giants and regional players. Future growth will be driven by ongoing research and development into new and improved vaccines, coupled with increasing public-private partnerships focused on expanding vaccination access in underserved regions. The continued expansion of the childhood vaccines market is underpinned by a confluence of factors. Governmental support through robust immunization programs, coupled with ongoing investment in vaccine R&D, is a crucial element. This includes not only developing new vaccines but also improving existing ones to increase efficacy and safety. The market's segmentation reflects the diversity of approaches to immunization. The success of specific vaccine types (such as recombinant and viral vaccines) will depend on their ability to address emerging disease strains and public health concerns. Regional variations will continue, reflecting both economic development levels and the prevalence of specific infectious diseases. Consequently, the forecast for continued growth is strong, but challenges remain, emphasizing the importance of public health education and collaborative strategies to enhance vaccine uptake and combat vaccine hesitancy.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

Europe Pediatric Vaccines Market growth is driven by increasing demand for vaccines, government support for immunization programs, and technological advancements in vaccine formulations and delivery systems.

The global vaccines market exhibits robust growth, driven by increasing disease prevalence, rising vaccination rates, and continuous technological advancements in vaccine development. The market's expansion is fueled by several key factors. Firstly, the heightened awareness of preventable diseases and the associated health risks are prompting governments and healthcare organizations to implement comprehensive vaccination programs globally. Secondly, the emergence of novel vaccines, such as mRNA vaccines, has significantly broadened the scope of vaccine applications and improved efficacy. Thirdly, the continuous research and development efforts aimed at creating more effective and safer vaccines, particularly for challenging diseases like influenza and HIV, contribute to the market's dynamic growth. While the market faces challenges like vaccine hesitancy and supply chain complexities in certain regions, the overall trajectory remains positive, with a projected substantial increase in market value over the forecast period. Specific segments, such as recombinant and viral vaccines, are expected to witness particularly rapid growth, driven by their higher efficacy and safety profiles compared to traditional vaccines. Geographic variations exist, with North America and Europe currently dominating the market, while Asia-Pacific is projected to exhibit significant growth in the coming years due to rising disposable incomes and improved healthcare infrastructure. The competitive landscape comprises major pharmaceutical companies alongside emerging players, fostering innovation and driving further market expansion. The market segmentation by application reveals a diverse portfolio of vaccines addressing various infectious diseases. Rabies, influenza, HPV, and Hepatitis vaccines represent significant portions of the market, reflecting the prevalence and impact of these diseases globally. However, the market also sees significant investment in vaccines for less prevalent yet equally important diseases, such as leprosy and JE. The segment based on vaccine type showcases the evolution of vaccine technology, with recombinant and viral vaccines leading the innovation and growth. This shift signifies a transition towards more effective, targeted, and safer vaccine options. The regional breakdown highlights the established dominance of developed markets but also emphasizes the significant growth potential of emerging economies, particularly in Asia-Pacific, driven by increasing populations, improving healthcare access and government-sponsored vaccination programs. This diverse landscape ensures the vaccines market remains a dynamic and promising sector with significant implications for global public health.

Europe Therapeutic Vaccines Market is poised for substantial growth, driven by technological advancements, increasing incidences of chronic diseases.

As of July 21, 2022, almost 86 percent of adults in Iceland had received a booster vaccine against COVID-19. Receiving an additional COVID-19 vaccine was recommended for those who were already fully vaccinated in order to maintain higher immunity against the disease. In Malta, 80.8 percent of adults had received an additional dose of a COVID-19 vaccine, as well as 79.9 percent of adults in Italy. On the other hand, only 11 percent of adults in Romania had received a booster vaccine.

Furthermore, the seven-day rate of cases across Europe shows which countries are currently worst affected by the situation. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

As of January 17, 2023, 96.3 percent of adults in Ireland had been fully vaccinated against COVID-19. According to the manufacturers of the majority of COVID-19 vaccines currently in use in Europe, being fully vaccinated is when a person receives two doses of the vaccine. In Portugal, 94.2 percent of adults had received a full course of the COVID-19 vaccination, as well as 93.9 percent of those in Malta had been fully vaccinated. On the other hand, only 35.8 percent of adults in Bulgaria had been fully vaccinated.

Furthermore, the seven-day rate of cases across Europe shows which countries are currently worst affected by the situation. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.